Literature DB >> 22357997

Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?

Haruo Watanabe1, Masayuki Kanematsu, Satoshi Goshima, Mariko Yoshida, Hiroshi Kawada, Hiroshi Kondo, Noriyuki Moriyama.   

Abstract

OBJECTIVE: The purpose of our study was to determine whether gadoxetate disodium-enhanced MRI improves the detection of locally recurrent hepatocellular carcinoma (HCC) after radiofrequency ablation therapy.
MATERIALS AND METHODS: Forty-two consecutive patients (26 men and 16 women; mean age, 70.9 years) who had undergone radiofrequency ablation therapy for HCC were examined by gadoxetate disodium-enhanced MRI. Three independent radiologists reviewed two sets of MR images separately. Set 1 contained unenhanced T1-weighted, T2-weighted, and contrast-enhanced extracellular phase images, and set 2 contained unenhanced T1-weighted, T2-weighted, and contrast-enhanced extracellular and hepatocyte phase images. Diagnostic accuracies were determined by receiver operating characteristic (ROC) curve analysis.
RESULTS: Of the 61 ablated lesions included, 10 developed local recurrence and 51 did not. Sensitivity (60-80% and 70-80% for sets 1 and 2, respectively), specificity (90-98% and 92-100%), and accuracy (87-95% and 89-97%) were not improved by adding hepatocyte phase images. Rather, mean area under the ROC curve (AUC) significantly decreased from 0.94 for set 1 to 0.82 for set 2 (p = 0.046), and the AUC of the radiologist with the least experience significantly decreased from 0.91 to 0.75 (p = 0.037).
CONCLUSION: For gadoxetate disodium-enhanced MRI, the detection of local recurrence of HCC after radiofrequency ablation therapy was not found to be improved by including hepatocyte phase images. Furthermore, detection may be further impaired when a less-experienced radiologist interprets the images.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22357997     DOI: 10.2214/AJR.11.6844

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  8 in total

Review 1.  Assessing locoregional treatment response to Hepatocellular Carcinoma: comparison of hepatobiliary contrast agents to extracellular contrast agents.

Authors:  Anum Aslam; Amita Kamath; Bradley Spieler; Mark Maschiocchi; Carl F Sabottke; Victoria Chernyak; Sara C Lewis
Journal:  Abdom Radiol (NY)       Date:  2021-04-15

Review 2.  Therapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.

Authors:  Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Safety margin of radiofrequency ablation for hepatocellular carcinoma: a prospective study using magnetic resonance imaging with superparamagnetic iron oxide.

Authors:  Kuniaki Fukuda; Kensaku Mori; Naoyuki Hasegawa; Katsuhiro Nasu; Kazunori Ishige; Yoshikazu Okamoto; Masanari Shiigai; Masato Abei; Manabu Minami; Ichinosuke Hyodo
Journal:  Jpn J Radiol       Date:  2019-05-17       Impact factor: 2.374

Review 4.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

Review 5.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

6.  Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging.

Authors:  Elmar M Merkle; Christoph J Zech; Carlo Bartolozzi; Mustafa R Bashir; Ahmed Ba-Ssalamah; Alexander Huppertz; Jeong Min Lee; Jens Ricke; Michiie Sakamoto; Claude B Sirlin; Sheng-Long Ye; Mengsu Zeng
Journal:  Eur Radiol       Date:  2015-06-13       Impact factor: 5.315

Review 7.  Interreader Reliability of Liver Imaging Reporting and Data System Treatment Response: A Systematic Review and Meta-Analysis.

Authors:  Dong Wook Kim; Sang Hyun Choi; Ji Sung Lee; So Yeon Kim; So Jung Lee; Jae Ho Byun
Journal:  Diagnostics (Basel)       Date:  2021-02-04

8.  Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan-Experience of High Volume Oncologic Institute.

Authors:  Vincenza Granata; Mario Petrillo; Roberta Fusco; Sergio Venanzio Setola; Elisabetta de Lutio di Castelguidone; Orlando Catalano; Mauro Piccirillo; Vittorio Albino; Francesco Izzo; Antonella Petrillo
Journal:  Gastroenterol Res Pract       Date:  2013-11-12       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.